{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of 95% CI were not available due to censoring.","groupId":"OG000","lowerLimit":"61.5","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI were not available due to censoring.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI were not available due to censoring.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"38"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Duration of response in \"responders\" was defined as any participants who achieved ≤1% BCR-ABL1IS (MR2) at any time during the study. Responders were defined as those participants who met all of the following: were randomized and treated, responded at 12 months after the initiation of study treatment, and underwent baseline polymerase chain reaction (PCR) assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (i.e., participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Overall number of participants analyzed is the number of participants with MR2.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 8.9 years","title":"Duration of Response in MR2 Responders","type":"SECONDARY","unitOfMeasure":"months"}